Incidence and risk of hypertension with pazopanib in patients with cancer: A meta-analysis

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 431-439

  Qi, Wei Xiang ^a   Lin, Feng ^a   Sun, Yuan Jue ^a   Tang, Li Na ^a   He, Ai Na ^a   Yao, Yang ^a   Shen, Zan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Hypertension; Meta analysis; Pazopanib; Tyrosine kinase inhibit

Indexed keywords

LAPATINIB; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB;

ARTICLE; BREAST CANCER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NASOPHARYNX CARCINOMA; OVARY CANCER; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE SARCOMA; SOLID TUMOR; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; INCIDENCE; NEOPLASMS; PROSPECTIVE STUDIES; PUBLICATION BIAS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK; SULFONAMIDES;

EID: 84874117127     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2025-5     Document Type: Article

References (45)

1. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909-1914
2. Tie J, Desai J (2012) Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog 17(1):51-67
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400
4. US Food and Drug Administration. Highlights of Prescribing Information. Votrient (pazopanib) tablets. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/022465lbl.pdf. Accessed 11 Jun 2012
5. European Medicines Agency. CHMPassessment report Votrient. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/001141/WC500094275.pdf. Accessed 11 Jun 2012
6. Bukowski RM, Yasothan U, Kirkpatrick P (2010) Pazopanib. Nat Rev Drug Discov 9(1):17-18
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061-1068
8. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879-1886
9. National Cancer Institute: Clinical trial search results. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10710684 Accessed 11 Jun 2012
10. van Geel RM, Beijnen JH, Schellens JH (2012) Concise drug review: pazopanib and axitinib. Oncologist 17:1081-1089
11. Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A et al (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer 48:3171-3176
12. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM et al (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24):7271-7278
13. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512
14. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A et al (2010) Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46(13):2432-2440
15. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A et al (2011) Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104(5):741-745
16. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117-123
17. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9-17
18. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC et al (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012-2021
19. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P et al (2010) A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 15(8):810-818
20. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11(10):962-972
21. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139(11):901-906
22. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm
23. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280-2285
24. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123-137
25. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335-371
26. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
27. Hutson TE, Davis ID, Machiels JPH, De Souza PL, Rottey S (2009) Hong Bf, et al. Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 28(3):475-480
28. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27(19):3126-3132
29. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28(19):3131-3137
30. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM et al (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119(1):32-37
31. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA et al (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12(8):855-861
32. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 8(22):3562-3569
33. Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B et al (2011) A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 17(16):5481-5489
34. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ et al (2011) A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis 15(1):87-92
35. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810-816
36. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB et al (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 66(8):813-821
37. Sica DA (2006) Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24(9):1329-1331
38. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24(9):1363-1369
39. Ravaud A, Sire M (2009) Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 20(5):966-967 author reply 967
40. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123(10):754-762
41. Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgren G, Hao X et al (2005) Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens 18(10):1347-1352
42. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K (2005) Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 28(2):147-153
43. Grunwald V, Heinzer H, Fiedler W (2007) Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 30(10):519-524
44. Agabiti-Rosei E (2003) Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 63(1):19-29
45. Lane PW (2012) Meta-analysis of incidence of rare events. Stat Methods Med Res. doi: 10.1177/0962280211432218